Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

BACKGROUND AND PURPOSE: There is a lack of evidence guiding discontinuation of disease‐modifying therapy (DMT) in relapsing multiple sclerosis (RMS). Thus, the objective of this study was to generate and validate a risk score for disease reactivation after DMT discontinuation in RMS. METHODS: We dre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bsteh, Gabriel, Hegen, Harald, Riedl, Katharina, Altmann, Patrick, Auer, Michael, Berek, Klaus, Di Pauli, Franziska, Ehling, Rainer, Kornek, Barbara, Monschein, Tobias, Rinner, Walter, Schmied, Christiane, Wurth, Sebastian, Zebenholzer, Karin, Zinganell, Anne, Zrzavy, Tobias, Zulehner, Gudrun, Deisenhammer, Florian, Rommer, Paulus, Leutmezer, Fritz, Berger, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248019/
https://www.ncbi.nlm.nih.gov/pubmed/33370478
http://dx.doi.org/10.1111/ene.14705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248019/
https://www.ncbi.nlm.nih.gov/pubmed/33370478
http://dx.doi.org/10.1111/ene.14705

Ejemplares similares